Company intelligence
FOMAT
Clinical trials embedded at the point of care
About FOMAT
Overview FOMAT is an Embedded Research Organization with 80+ sites across 6 states in the U.S., bringing clinical trials closer to patients through community-based care. We work with physician groups to expand access to Phase I to IV studies for diverse patient populations, supported by advanced facilities and dedicated research teams. Key Highlights • 80+ sites across 7 states • 40+ Principal Investigators • 1.7 million patients Awards and Recognition • Innovative Business of the Year, Oxnard Chamber of Commerce, 2020 • Site Excellence in Patient Inclusion Award nominee, 2022 • Site Tank Award winner for AllzWell by FOMAT, 2023 • Excellence in Patient Centricity Award winner, SCRS, 2024 • ViE Awards nominee as part of hyperCORE, 2024 • ViE Awards nominee for Best Clinical Trial Company, 2025 Therapeutic Areas Allergy and Immunology, Cardiology, Family and Internal Medicine, Gastroenterology, Infectious Diseases and Vaccines, Metabolic and Endocrinology, Nephrology, Obstetrics and Gynecology, Ophthalmology and Retina, Oncology, Pediatrics, Rheumatology, Urology, and Wound Care. Headquartered in Oxnard, California.
Verified activity
Signals from FOMAT
4 published signals
Presence & Recognition
FOMAT will be represented by Steve Schlesinger at ASN Kidney Week 2026 in Denver from October 21 to 25.
Reported by FOMAT
Research & Knowledge
FOMAT announced that awareness saves time for patients with ovarian cancer, as late-stage referrals, narrow eligibility windows, and fragmented care journeys make it harder to build trials.
Reported by FOMAT
Presence & Recognition
FOMAT will be represented by Principal Investigators Erica Cohen, MD, and Antoine Jakiche, MD, at ACG 2026 in Nashville, Tennessee, from October 9 to 14.
Reported by FOMAT
Presence & Recognition
FOMAT is attending the SCRS Global Site Solutions Summit 2026 in Orlando from October 15 to 18.
Reported by FOMAT